FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer

FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer. FDA approvs new warnings about this risk to the prescribing information and Patient Package Insert for the entire class of these cyclin-dependent kinase 4/6.

Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news